In this article, we will discuss the 10 Unstoppable Stocks That Could Double Your Money.
On April 16, Fundstrat’s Tom Lee joined ‘Closing Bell’ on CNBC to discuss what to expect from equity markets going forward. Lee maintained that the market is currently in a better position than it was earlier in the year when it reached its all-time high. He identified three primary reasons for this outlook: the US market has demonstrated an ability to handle surges in oil prices that negatively impact other countries; earnings have risen, suggesting the war is providing economic stimulus; and an examination of historical oil spikes indicates that the impact on core inflation is less severe than previously assumed. Consequently, Lee maintained his base case for the S&P 500 to hit 7,300 as part of his three-phase market outlook before any potential larger drawdown occurs.
Lee characterized the US economy as the best house in a now more uncertain neighborhood and noted that this conflict is the seventh black swan event investors have faced since 2020. He pointed out that while other nations face factory shutdowns and economic closures, the US economy continues to operate effectively despite a Middle East catastrophe that has effectively closed the Strait. While Lee acknowledged that the existence of downside tail risks (such as shocks from commodities like helium affecting the US) he believes that the size of this risk has shrunk. He added that there is also a positive tail risk wherein a lasting ceasefire would make any immediate economic shock short enough that it would not disrupt his primary outlook.
Lee defended tech as an attractive investment and noted that these companies possess true moats and have consistently grown earnings faster than the S&P 500. He explained that because tech valuations have fallen to market multiples while earnings growth estimates remain solid or are increasing, the stocks appear more attractive. He concluded that these companies are positioned as winners in the AI revolution, and he believes that in five years, investors will be surprised that these assets were available at such cheap multiples today.
Our Methodology
We used screeners to identify stocks with a market capitalization exceeding $2 billion. We then looked for stocks that have gained over 20% year-to-date and have an average upside potential of over 100%. We limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Note: All data was sourced on April 16.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
10 Unstoppable Stocks That Could Double Your Money
10. Cue Biopharma Inc. (NASDAQ:CUE)
Cue Biopharma Inc. (NASDAQ:CUE) is one of the unstoppable stocks that could double your money. On March 27, Cue Biopharma announced a leadership transition, appointing Lucinda Warren as interim president and chief executive officer. Warren, who joined the company in 2024 and most recently served as chief financial & business officer, succeeds Usman Azam. Dr. Azam stepped down from his executive roles and the board of directors as of March 26.
Warren brings over 30 years of global pharmaceutical and biotechnology experience to the position, including a significant tenure at Johnson & Johnson, where she led business development for neuroscience and the Japan region. During her time at Cue Biopharma, she has been instrumental in executing several high-value strategic transactions. These include the return of worldwide rights for CUE-401, a collaboration with Boehringer Ingelheim for CUE-501, and a license agreement with ImmunoScape for solid tumor cell therapies.
The board of directors expressed full support for Warren as she leads the company through this transition period. The company’s immediate priority remains the advancement of its lead candidate, CUE-401, into clinical trials by H2 2026. Management continues to focus on developing its novel class of therapeutic biologics for autoimmune and inflammatory diseases while pursuing creative deals to enhance shareholder value.
Cue Biopharma Inc. is a biopharma company that deals in injectable therapeutics to engage & modulate targeted, disease-relevant T cells. The company develops a pipeline of preclinical & clinical immunotherapy candidates, such as lead products CUE-401 for immune tolerance and CUE-501 for autoimmune diseases, alongside CUE-101 and CUE-102 for various cancers.
9. XTI Aerospace Inc. (NASDAQ:XTIA)
XTI Aerospace Inc. (NASDAQ:XTIA) is one of the unstoppable stocks that could double your money. On April 15, XTI Aerospace reported Q4 and 2025 results. This period was marked by the acquisition of Drone Nerds LLC and Anzu Robotics LLC. Following the November 2025 merger, the company reported annual revenue of $22.5 million and a gross profit of $4.9 million. On a pro forma basis (treating the acquisition as if it had occurred at the start of 2024), the company’s full-year performance reached $121.6 million in revenue with a gross profit of $26.8 million, representing a 22% margin.
Q4 was highlighted by the completion of the ~$40 million acquisition of Drone Nerds, a major US drone solutions provider. This move was supported by a $25 million strategic investment from Unusual Machines. Additionally, XTI Aerospace allied with Valkyrie Intelligence LLC to utilize the extensive drone industry data sets established by its newly acquired divisions. These corporate developments have transformed XTI Aerospace into a multifaceted aerospace and defense firm operating across drone distribution, unmanned systems, and advanced manufacturing.
For 2026, XTI Aerospace Inc. issued optimistic guidance, projecting full-year revenue to reach $160 million or greater. Despite reporting a pro forma net loss from continuing operations of $39.0 million for 2025, the company is focused on scaling its enterprise and government drone solutions platform. Management intends to capitalize on its 3 dedicated divisions and its partnership with Valkyrie Sciences to drive growth and harness intelligence-led opportunities in the unmanned systems market.
XTI Aerospace Inc. is an aircraft development company that offers TriFan 600, which is a vertical takeoff & landing aircraft, as well as real-time location systems, indoor intelligence software, and hardware products.
8. Adagene Inc. (NASDAQ:ADAG)
Adagene Inc. (NASDAQ:ADAG) is one of the unstoppable stocks that could double your money. On April 2, Adagene announced a clinical collaboration with Incyte Corp. (NASDAQ:INCY) to evaluate a novel combination therapy for microsatellite stable colorectal cancer/MSS CRC. The study will combine Adagene’s muzastotug/ADG126, which is a masked anti-CTLA-4 SAFEbody, with Incyte’s INCA33890, a bispecific antibody targeting TGFβR2 and PD-1.
This Phase 1 trial, expected to begin in 2026, will focus on third-line patients both with and without liver metastases, a group that typically faces a poor prognosis and limited response to standard immunotherapies. The collaboration uses muzastotug’s potential as a backbone therapy, designed to increase the therapeutic index by selectively activating in the tumor microenvironment. While Incyte will sponsor and conduct the trial, Adagene will provide the clinical supply of muzastotug.
This marks a significant expansion of muzastotug’s clinical portfolio, which already includes promising data in combination with pembrolizumab, where it achieved a 31% overall response rate in specific high-dose cohorts for late-line MSS CRC patients. Additionally, Adagene Inc. recently released updated data from its ongoing Phase 1b/2 study, showing that muzastotug in combination with pembrolizumab achieved a median overall survival of 19.8 months in the 10 mg/kg cohorts.
Adagene Inc. is a biotechnology company that specializes in monoclonal antibody drugs for cancers. The company’s diverse pipeline of clinical & preclinical oncology candidates includes its lead anti-CTLA-4 antibody ADG126 and various mAb & bispecific programs.
7. Namib Minerals (NASDAQ:NAMM)
Namib Minerals (NASDAQ:NAMM) is one of the unstoppable stocks that could double your money. On April 2, Namib reported its full-year 2025 financial results, highlighting a year of strategic transition and infrastructure investment. The company produced ~25,000 ounces of gold, generating $82.6 million in revenue. Despite a lower-grade environment at its flagship How Mine, adjusted EBITDA grew by 18% to $29.0 million, supported by an increase in realized gold prices.
The company also reported a substantial net profit of $101.2 million, largely driven by non-cash gains related to the revaluation of liabilities following its public listing. Operational highlights for the year include steady progress on the capacity expansion at the How Mine, which aims to increase milling throughput from 40,500 to 55,000 tonnes per month by H2 2026.
Additionally, the company reached a critical milestone in its Redwing Mine restart program with the commencement of dewatering activities in early 2026. This eight-month process is expected to conclude late in the year, paving the way for the site’s return to production. Namib is currently evaluating non-dilutive funding options to support the capital requirements for these brownfield growth projects. For 2026, Namib Minerals has issued guidance projecting gold production between 28,000 and 31,500 ounces and adjusted EBITDA in the range of $50 million to $62 million.
Namib Minerals is a gold producer, developer, and explorer focused on Zimbabwe. The company operates the How Mine and aims to restart two additional assets in the country.
6. Onfolio Holdings Inc. (NASDAQ:ONFO)
Onfolio Holdings Inc. (NASDAQ:ONFO) is one of the unstoppable stocks that could double your money. On April 16, Onfolio entered into a $100 million equity facility agreement with an institutional investor to accelerate its acquisition-led growth strategy. This facility provides the company with flexible, discretionary capital intended for the purchase of undervalued, cash-generative online businesses and the expansion of its digital asset reserve.
The company’s growth plan centers on an AI-native operating model designed to improve margins and scale high-margin managed services. By utilizing frontier AI models, Onfolio provides enterprise-grade marketing, data analytics, and automation solutions through an asset-light approach. The company is currently rolling out these AI services across its B2B segment to drive operational efficiency while using enhanced data analytics to bolster its B2C portfolio.
This new equity facility, combined with an existing convertible note facility, is designed to support the compounding of value across Onfolio’s diverse operating portfolio. A portion of the capital will also be used to grow the company’s yield-generating digital asset treasury. Management believes that as the portfolio expands, the specialized AI services layer will become a critical component in scaling the platform and delivering long-term value to shareholders.
Onfolio Holdings Inc. is a communication services company that was founded in 2019 and acquires & develops internet businesses in two segments: B2B and B2C.
5. XWELL Inc. (NASDAQ:XWEL)
XWELL Inc. (NASDAQ:XWEL) is one of the unstoppable stocks that could double your money. On April 1, XWELL announced financial results for the full year 2025, reporting total revenue of ~$29.2 million. The company showed increased operational efficiency, with total operating expenses decreasing by 10% and G&A costs dropping by 20% year-over-year. While the company reported an operating loss of ~$15.7 million, it significantly supported its liquidity post-fiscal year-end through a $31.3 million private placement intended to fund debt repurchases, stock redemptions, and general corporate needs.
Throughout 2025 and early 2026, XWELL focused on diversifying its wellness services beyond traditional airport locations. Notable expansions included the opening of a tech-forward wellness center in New York City’s Penn Station and new locations in Florida markets like Brandon and Waterford Lakes. These efforts were complemented by high-profile community engagements, such as a multiyear partnership naming XWELL the official wellness spa of the Orlando Magic.
The company also continues to expand its global biosecurity footprint through its XpresCheck segment. In early 2026, XWELL Inc. entered a partnership with PieQ to develop an AI-driven biosecurity forecasting platform for the CDC and appointed Dr. Cindy Friedman, a former CDC senior advisor, to guide its international surveillance initiatives. These developments build on a 3-year extension of the Traveler-based Genomic Surveillance program secured in 2025, as the company seeks to apply its pathogen detection models to global travel hubs and major international mass gathering events.
XWELL Inc. is a diagnostics & research company that provides health & wellness services to travelers in four segments: XpresSpa, XpresTest, Naples Wax Center, and Treat. The company was known as XpresSpa Group until October 2022.
4. Cyclerion Therapeutics Inc. (NASDAQ:CYCN)
Cyclerion Therapeutics Inc. (NASDAQ:CYCN) is one of the unstoppable stocks that could double your money. On April 1, Cyclerion and Korsana Biosciences entered into a definitive merger agreement to form a combined entity operating under the name Korsana Biosciences, trading under the ticker ‘KRSA’. The merger aims to advance Korsana’s neurodegenerative disease pipeline, headlined by KRSA-028, a next-gen antibody targeting amyloid beta for Alzheimer’s disease.
This lead program uses the proprietary THETA platform, which is designed to improve brain delivery and safety while offering the convenience of subcutaneous administration. In conjunction with the merger, Korsana secured $380 million in private financing from a syndicate of leading healthcare investors, including Fairmount and Venrock Healthcare Capital Partners. This capital is expected to fund operations into 2029, providing the necessary runway to reach critical clinical milestones.
Key upcoming data readouts include Phase 1 healthy volunteer results in mid-2027 and interim proof-of-concept data regarding amyloid plaque clearance in Alzheimer’s patients by the end of 2027. The transaction follows a review by Cyclerion Therapeutics Inc. and represents an opportunity to use Korsana’s innovative platform, which was developed in partnership with Paragon Therapeutics.
Cyclerion Therapeutics Inc. is a biotech company that deals with serious diseases with novel sGC stimulators in the CNS and the periphery. The company is licensed by Akebia to develop Praliciguat and related products, including medical affairs.
3. Eledon Pharmaceuticals Inc. (NASDAQ:ELDN)
Eledon Pharmaceuticals Inc. (NASDAQ:ELDN) is one of the unstoppable stocks that could double your money. On March 19, Eledon reported its financial results for the full year 2025, highlighting the clinical advancement of its anti-CD40L antibody, tegoprubart. The company announced that tegoprubart received FDA Orphan Drug designation for preventing allograft rejection in liver transplantation, adding to its existing designations for pancreatic islet cell transplantation and ALS.
Clinical data from a Phase 1b long-term extension study in kidney transplantation showed a favorable safety profile over 24 months, with no reported graft losses or rejection episodes and an improvement in mean estimated glomerular filtration rate. In a University of Chicago Medicine-led study, tegoprubart showed promising results in treating type 1 diabetes via islet transplantation. For 2026, Eledon anticipates receiving FDA guidance for a Phase 3 trial in kidney transplantation and plans to initiate new investigator-led studies in liver and islet cell transplantation.
Financial results for 2025 reflected increased investment in clinical programs, with R&D expenses rising to $66.3 million from $52 million in the previous year. This increase was driven by expanded trial activities, manufacturing scale-up, and additional personnel. Eledon Pharmaceuticals Inc. reported a net loss of $45.6 million for the year, which included a $33.4 million non-cash gain from changes in the fair value of warrant liabilities.
Eledon Pharmaceuticals Inc. is a clinical-stage biotechnology company that targets the CD40L pathway to develop ALS treatments and therapies to prevent organ transplant rejection. The company’s lead candidate, tegoprubart, is an anti-CD40L IgG1 antibody.
2. Edesa Biotech Inc. (NASDAQ:EDSA)
Edesa Biotech Inc. (NASDAQ:EDSA) is one of the unstoppable stocks that could double your money. On March 26, Edesa reaffirmed that enrollment for its Phase 2 clinical study of EB06, which is a treatment for moderate-to-severe nonsegmental vitiligo, is on track to begin in mid-2026. The company has selected JSS Medical Research as its clinical research organization and has initiated outreach to potential clinical sites. Recruitment is expected to start at investigational sites in Canada, following the approval of the company’s clinical trial application.
The upcoming study will evaluate the safety and efficacy of EB06, a monoclonal antibody designed to target the chemokine CXCL10, which plays a critical role in the destruction of skin pigment cells. By neutralizing this protein, EB06 aims to prevent and reverse the depigmentation associated with vitiligo. The CEO emphasized that the trial design has been refined through discussions with key opinion leaders to address the significant need for effective systemic therapeutics in a market with few approved options.
EB06 has already shown biological activity and a favorable safety profile in three previous clinical studies involving 65 subjects. While the current Phase 2 trial will use an intravenous formulation, Edesa Biotech Inc. is also developing a subcutaneous version for future clinical evaluation.
Edesa Biotech Inc. is a clinical-stage biotech company that was founded in 2015. The company researches, develops, manufactures, and commercializes products for inflammatory and immune-related diseases.
1. TuHURA Biosciences Inc. (NASDAQ:HURA)
TuHURA Biosciences Inc. (NASDAQ:HURA) is one of the unstoppable stocks that could double your money. TuHURA announced its financial results for Q4 and the full year. The company is advancing its Phase 3 trial for IFx-2.0 as an adjunctive treatment for Merkel Cell Carcinoma/MCC under an FDA Special Protocol Assessment, with enrollment expected to conclude in mid-2027. To support its development pipeline, TuHURA acquired Kineta’s VISTA-inhibiting antibody, TBS-2025, for $10.5 million and appointed Dr. Craig Tendler to provide oversight for clinical operations.
Significant corporate milestones include the initiation of a Phase 1b/2a study for IFx-2.0 in patients with metastatic MCC of unknown primary origin and the presentation of data at ASH identifying the Delta Opioid Receptor as a target for overcoming immunotherapy resistance. For 2026, the company expects to receive Orphan Drug Designation for IFx-2.0 in MCC and plans to meet with the FDA regarding TBS-2025’s development in AML. Additionally, TuHURA aims to select its lead antibody-drug conjugate and initiate proof-of-concept studies within the second half of the year.
TuHURA Biosciences Inc. reported $3.6 million in cash and cash equivalents at the end of 2025, supplemented by $7.5 million received in early 2026. Annual R&D expenses rose to $20.5 million, reflecting increased investment in its clinical programs compared to the previous year. The company successfully raised $21.2 million through private placements and offerings during this period, supporting its ongoing efforts to develop novel immuno-oncology therapeutics.
TuHURA Biosciences Inc. is a clinical-stage biotech firm that develops novel immuno-oncology technologies for cancer treatment. The company was formerly known as Morphogenesis until December 2023.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
